Modelling prefrontal cortex deficits in schizophrenia: implications for treatment

J.A. Pratt, C. Winchester, A. Egerton, S.M. Cochran, B.J. Morris

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Current treatments of schizophrenia are compromised by their inability to treat all symptoms of the disease and their side-effects. Whilst existing antipsychotic drugs are effective against positive symptoms, they have negligible efficacy against the prefrontal cortex (PFC)-associated cognitive deficits and negative symptoms. New models that reproduce core pathophysiological features of schizophrenia are more likely to have improved predictive validity in identifying new treatments. We have developed a NMDA receptor antagonist model that reproduces core PFC deficits of schizophrenia and discuss this in relation to pathophysiology and treatments. Subchronic and chronic intermittent PCP (2.6 mg/kg i.p.) was administered to rats. PFC activity was assessed by 2-deoxyglucose imaging, parvalbumin and Kv3.1 mRNA expression, and the attentional set-shifting test (ASST) of executive function. Affymetrix gene array technology was employed to examine gene expression profile patterns. PCP treatment reduced glucose utilization in the PFC (hypofrontality). This was accompanied by a reduction in markers of GABAergic interneurones ( parvalbumin and Kv3.1 mRNA expression) and deficits in the extradimensional shift dimension of the ASST. Consistent with their clinical profile, the hypofrontality was not reversed by clozapine or haloperidol. Transcriptional analysis revealed patterns of change consistent with current neurobiological theories of schizophrenia. This model mirrors core neurobiological deficits of schizophrenia; hypofrontality, altered markers of GABAergic interneurone activity and deficits in executive function. As such it is likely to be a valuable translational model for understanding the neurobiological mechanisms underlying hypofrontality and for identifying and validating novel drug targets that may restore PFC deficits in schizophrenia.
Original languageEnglish
Pages (from-to)S465-S470
JournalBritish Journal of Pharmacology
Volume153
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Prefrontal Cortex
Schizophrenia
Parvalbumins
Executive Function
Interneurons
Messenger RNA
Clozapine
Deoxyglucose
Haloperidol
N-Methyl-D-Aspartate Receptors
Transcriptome
Antipsychotic Agents
Technology
Glucose
Pharmaceutical Preparations
Genes

Keywords

  • schizophrenia
  • chronic PCP
  • hypofrontality
  • translational model
  • prefrontal cortex
  • gene expression
  • cognitive flexibility
  • transcriptomics
  • PCP
  • phencyclidine

Cite this

Pratt, J.A. ; Winchester, C. ; Egerton, A. ; Cochran, S.M. ; Morris, B.J. / Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. In: British Journal of Pharmacology. 2008 ; Vol. 153. pp. S465-S470.
@article{113d18bfe4654cdaaca3c5966d4fca27,
title = "Modelling prefrontal cortex deficits in schizophrenia: implications for treatment",
abstract = "Current treatments of schizophrenia are compromised by their inability to treat all symptoms of the disease and their side-effects. Whilst existing antipsychotic drugs are effective against positive symptoms, they have negligible efficacy against the prefrontal cortex (PFC)-associated cognitive deficits and negative symptoms. New models that reproduce core pathophysiological features of schizophrenia are more likely to have improved predictive validity in identifying new treatments. We have developed a NMDA receptor antagonist model that reproduces core PFC deficits of schizophrenia and discuss this in relation to pathophysiology and treatments. Subchronic and chronic intermittent PCP (2.6 mg/kg i.p.) was administered to rats. PFC activity was assessed by 2-deoxyglucose imaging, parvalbumin and Kv3.1 mRNA expression, and the attentional set-shifting test (ASST) of executive function. Affymetrix gene array technology was employed to examine gene expression profile patterns. PCP treatment reduced glucose utilization in the PFC (hypofrontality). This was accompanied by a reduction in markers of GABAergic interneurones ( parvalbumin and Kv3.1 mRNA expression) and deficits in the extradimensional shift dimension of the ASST. Consistent with their clinical profile, the hypofrontality was not reversed by clozapine or haloperidol. Transcriptional analysis revealed patterns of change consistent with current neurobiological theories of schizophrenia. This model mirrors core neurobiological deficits of schizophrenia; hypofrontality, altered markers of GABAergic interneurone activity and deficits in executive function. As such it is likely to be a valuable translational model for understanding the neurobiological mechanisms underlying hypofrontality and for identifying and validating novel drug targets that may restore PFC deficits in schizophrenia.",
keywords = "schizophrenia, chronic PCP, hypofrontality, translational model, prefrontal cortex, gene expression, cognitive flexibility, transcriptomics, PCP, phencyclidine",
author = "J.A. Pratt and C. Winchester and A. Egerton and S.M. Cochran and B.J. Morris",
year = "2008",
month = "3",
doi = "10.1038/bjp.2008.24",
language = "English",
volume = "153",
pages = "S465--S470",
journal = "British Journal of Pharmacology",
issn = "0007-1188",

}

Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. / Pratt, J.A.; Winchester, C.; Egerton, A.; Cochran, S.M.; Morris, B.J.

In: British Journal of Pharmacology, Vol. 153, 03.2008, p. S465-S470.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Modelling prefrontal cortex deficits in schizophrenia: implications for treatment

AU - Pratt, J.A.

AU - Winchester, C.

AU - Egerton, A.

AU - Cochran, S.M.

AU - Morris, B.J.

PY - 2008/3

Y1 - 2008/3

N2 - Current treatments of schizophrenia are compromised by their inability to treat all symptoms of the disease and their side-effects. Whilst existing antipsychotic drugs are effective against positive symptoms, they have negligible efficacy against the prefrontal cortex (PFC)-associated cognitive deficits and negative symptoms. New models that reproduce core pathophysiological features of schizophrenia are more likely to have improved predictive validity in identifying new treatments. We have developed a NMDA receptor antagonist model that reproduces core PFC deficits of schizophrenia and discuss this in relation to pathophysiology and treatments. Subchronic and chronic intermittent PCP (2.6 mg/kg i.p.) was administered to rats. PFC activity was assessed by 2-deoxyglucose imaging, parvalbumin and Kv3.1 mRNA expression, and the attentional set-shifting test (ASST) of executive function. Affymetrix gene array technology was employed to examine gene expression profile patterns. PCP treatment reduced glucose utilization in the PFC (hypofrontality). This was accompanied by a reduction in markers of GABAergic interneurones ( parvalbumin and Kv3.1 mRNA expression) and deficits in the extradimensional shift dimension of the ASST. Consistent with their clinical profile, the hypofrontality was not reversed by clozapine or haloperidol. Transcriptional analysis revealed patterns of change consistent with current neurobiological theories of schizophrenia. This model mirrors core neurobiological deficits of schizophrenia; hypofrontality, altered markers of GABAergic interneurone activity and deficits in executive function. As such it is likely to be a valuable translational model for understanding the neurobiological mechanisms underlying hypofrontality and for identifying and validating novel drug targets that may restore PFC deficits in schizophrenia.

AB - Current treatments of schizophrenia are compromised by their inability to treat all symptoms of the disease and their side-effects. Whilst existing antipsychotic drugs are effective against positive symptoms, they have negligible efficacy against the prefrontal cortex (PFC)-associated cognitive deficits and negative symptoms. New models that reproduce core pathophysiological features of schizophrenia are more likely to have improved predictive validity in identifying new treatments. We have developed a NMDA receptor antagonist model that reproduces core PFC deficits of schizophrenia and discuss this in relation to pathophysiology and treatments. Subchronic and chronic intermittent PCP (2.6 mg/kg i.p.) was administered to rats. PFC activity was assessed by 2-deoxyglucose imaging, parvalbumin and Kv3.1 mRNA expression, and the attentional set-shifting test (ASST) of executive function. Affymetrix gene array technology was employed to examine gene expression profile patterns. PCP treatment reduced glucose utilization in the PFC (hypofrontality). This was accompanied by a reduction in markers of GABAergic interneurones ( parvalbumin and Kv3.1 mRNA expression) and deficits in the extradimensional shift dimension of the ASST. Consistent with their clinical profile, the hypofrontality was not reversed by clozapine or haloperidol. Transcriptional analysis revealed patterns of change consistent with current neurobiological theories of schizophrenia. This model mirrors core neurobiological deficits of schizophrenia; hypofrontality, altered markers of GABAergic interneurone activity and deficits in executive function. As such it is likely to be a valuable translational model for understanding the neurobiological mechanisms underlying hypofrontality and for identifying and validating novel drug targets that may restore PFC deficits in schizophrenia.

KW - schizophrenia

KW - chronic PCP

KW - hypofrontality

KW - translational model

KW - prefrontal cortex

KW - gene expression

KW - cognitive flexibility

KW - transcriptomics

KW - PCP

KW - phencyclidine

UR - http://dx.doi.org/10.1038/bjp.2008.24

U2 - 10.1038/bjp.2008.24

DO - 10.1038/bjp.2008.24

M3 - Article

VL - 153

SP - S465-S470

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

ER -